| Timothy Cooper King, MD | |
|
501 Billingsley Rd, Ste B, Charlotte, NC 28211-1009 | |
| (704) 444-2400 | |
| Not Available |
| Full Name | Timothy Cooper King |
|---|---|
| Gender | Male |
| Speciality | Psychiatry & Neurology - Psychiatry |
| Location | 501 Billingsley Rd, Charlotte, North Carolina |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043325046 | NPI | - | NPPES |
| Entity Name | Carolinas Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275774333 PECOS PAC ID: 4789597477 Enrollment ID: O20031110000116 |
News Archive
Bristol-Myers Squibb Company announced today that the Hart-Scott-Rodino (HSR) waiting period for its tender offer for ZymoGenetics, Inc. has expired.
Merck & Co have finally won the Food and Drugs Administration – FDA'S approval on Friday to sell a new drug considered a major advance against the liver-destroying hepatitis C virus. The drug brand named, Victrelis is expected to help transform treatment of the potentially fatal disease with higher cure rates and shorter courses of therapy for some patients. Merck shares rose 0.6 percent in after-hours trading to $37.33, up from their $37.08 close on the New York Stock Exchange. Approval of Victrelis was widely expected after a FDA advisory panel recommended the drug in an 18-0 vote in April.
Tekmira Pharmaceuticals Corporation, a leading developer of RNA interference therapeutics, announced today it has initiated patient dosing in a Phase 1 human clinical trial for its lead oncology product, TKM-PLK1. TKM-PLK1 targets polo-like kinase 1, or PLK1, a cell cycle protein involved in tumor cell proliferation and a validated oncology target.
It's a fairly common genetic condition that can surface as a series of dark skin spots and result in a host of maladies from tumors to premature cardiovascular disease. Medical College of Georgia researchers hope their studies of how neurofibromatosis 1, or NF1, can dangerously thicken or thin blood vessel walls will one day help physicians better identify and treat these young patients at cardiovascular risk.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Timothy Cooper King, MD Po Box 19305, Charlotte, NC 28219-9305 Ph: () - | Timothy Cooper King, MD 501 Billingsley Rd, Ste B, Charlotte, NC 28211-1009 Ph: (704) 444-2400 |
News Archive
Bristol-Myers Squibb Company announced today that the Hart-Scott-Rodino (HSR) waiting period for its tender offer for ZymoGenetics, Inc. has expired.
Merck & Co have finally won the Food and Drugs Administration – FDA'S approval on Friday to sell a new drug considered a major advance against the liver-destroying hepatitis C virus. The drug brand named, Victrelis is expected to help transform treatment of the potentially fatal disease with higher cure rates and shorter courses of therapy for some patients. Merck shares rose 0.6 percent in after-hours trading to $37.33, up from their $37.08 close on the New York Stock Exchange. Approval of Victrelis was widely expected after a FDA advisory panel recommended the drug in an 18-0 vote in April.
Tekmira Pharmaceuticals Corporation, a leading developer of RNA interference therapeutics, announced today it has initiated patient dosing in a Phase 1 human clinical trial for its lead oncology product, TKM-PLK1. TKM-PLK1 targets polo-like kinase 1, or PLK1, a cell cycle protein involved in tumor cell proliferation and a validated oncology target.
It's a fairly common genetic condition that can surface as a series of dark skin spots and result in a host of maladies from tumors to premature cardiovascular disease. Medical College of Georgia researchers hope their studies of how neurofibromatosis 1, or NF1, can dangerously thicken or thin blood vessel walls will one day help physicians better identify and treat these young patients at cardiovascular risk.
› Verified 7 days ago
Ryan Alan Williamson, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 200 Hawthorne Ln, Charlotte, NC 28204 Phone: 704-384-9437 | |
Soong Hyun Lee, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: Behavioral Health Center Cmc Randolph, 501 Billingsley Road, Charlotte, NC 28211 Phone: 704-358-2700 Fax: 704-358-2716 | |
Dr. Richard David Jacobson, MD, PHD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 4228 Brookfield Dr, Charlotte, NC 28210 Phone: 615-345-5400 | |
Stephanie Francis Newby, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 501 Billingsley Rd, Ste B, Charlotte, NC 28211 Phone: 704-444-2400 | |
Dr. T Hemanth Rao, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2607 E 7th St Ste 200, Charlotte, NC 28204 Phone: 704-449-6064 Fax: 704-731-0936 | |
Boris Maximovich Kiselev, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 501 Billingsley Rd, Ste B, Charlotte, NC 28211 Phone: 704-444-2400 | |
Dr. Sumul Modi, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 5500 Executive Center Dr Ste 206, Charlotte, NC 28212 Phone: 984-777-9940 Fax: 877-794-5929 |